Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pertuzumab + capecitabine
- Development stage
- Unknown
- Lead developer
- Genentech
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
**Pertuzumab + capecitabine** is a combination of two distinct antineoplastic agents used primarily in clinical trials for advanced or metastatic HER2-positive cancers. **Pertuzumab** is a humanized monoclonal antibody that inhibits HER2 dimerization, thereby blocking downstream signaling pathways involved in tumor cell growth and survival. **Capecitabine** is an oral prodrug of 5-fluorouracil (5-FU), a small molecule antimetabolite that interferes with DNA synthesis and repair by inhibiting thymidylate synthase. This combination has been explored especially in patients who progressed after standard HER2-directed therapies, showing tolerability and some disease stabilization in early-phase studies. The primary mechanism is **dual HER2 blockade with cytotoxic chemotherapy**[1][3].
- Brand names
- Perjeta + Xeloda
- Other names
- pertuzumab and capecitabine
02
Targets
TS (Thymidylate synthase)ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on pertuzumab + capecitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pertuzumab + capecitabine.